Table 5.
Summary of Baseline Minimum Inhibitory Concentration Results for Gepotidacin Against Neisseria gonorrhoeae in the Microbiologically Evaluable Population
| Specimen Source Treatment |
n | MIC Range | MIC50 (μg/mL) | MIC90 (μg/mL) | |
|---|---|---|---|---|---|
| Minimum (μg/mL) | Maximum (μg/mL) | ||||
| Urogenital | |||||
| Gepotidacin 1500 mg | 30 | ≤0.06 | 1 | 0.12 | 0.5 |
| Gepotidacin 3000 mg | 39 | ≤0.06 | 1 | 0.25 | 0.5 |
| Gepotidacin total | 69 | ≤0.06 | 1 | 0.12 | 0.5 |
| Pharyngeal | |||||
| Gepotidacin 1500 mg | ... | ... | ... | ... | ... |
| Gepotidacin 3000 mg | 2a | ≤0.06 | 0.12 | ... | ... |
| Gepotidacin total | 2a | ≤0.06 | 0.12 | ... | ... |
| Rectal | |||||
| Gepotidacin 1500 mg | 1 | 0.12 | 0.12 | ... | ... |
| Gepotidacin 3000 mg | 2 | 0.12 | 0.25 | ... | ... |
| Gepotidacin total | 3 | 0.12 | 0.25 | ... | … |
The MIC50 and MIC90 values were not reported if n <10.
Abbreviations: MIC, minimum inhibitory concentration; MIC50, minimum inhibitory concentration required to inhibit the growth of 50% of organisms; MIC90, minimum inhibitory concentration required to inhibit the growth of 90% of organisms.
aDue to specimen contamination, susceptibility testing could not be reliably performed on the pharyngeal isolate from 1 participant in the 3000-mg treatment group at baseline.